Abstract 611: MYC DNA methylation in prostate tumor tissue is associated with tumor aggressiveness

• Published in: Cancer research (Chicago, Ill.) Ill.), 2019-07, Vol.79 (13_Supplement), p.611-611
• Main Authors: Barry, Kathryn Hughes, Mohanty, Kareshma, Rose, Gary, Cellini, Ashley, Ambulos, Nicholas, Yin, Jing, Yan, Liying, Poulin, Matthew, Meyer, Ann, Zhang, Yuji, Bentzen, Søren, Burke, Allen, Hussain, Arif, Berndt, Sonja I.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2019-611

We previously reported an increased risk of aggressive, but not non-aggressive, prostate cancer associated with pre-diagnostic blood DNA methylation levels in exon 3 of the MYC oncogene among Caucasian men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. In the present study, we aimed to investigate MYC DNA methylation in prostate tissue in relation to tumor aggressiveness (based on Gleason score). We also aimed to investigate whether MYC methylation in prostate tissue is associated with race or tumor/normal status. We accessed formalin-fixed, paraffin-embedded prostate tumor and normal tissue from 50 Caucasian and 50 African American prostate cancer patients that underwent radical prostatectomy at the University of Maryland; for each race group, we selected 25 patients with a Gleason score of 7 and 25 with a Gleason score of 6. We systematically selected the most recent samples, and year of surgery for our patients ranged from 2001-2017. Age at surgery ranged from 42-75 years. We used pyrosequencing to measure DNA methylation at six CpG sites in MYC exon 3 (Chr8:128753145 - Chr8:128753221). We excluded 11 patients for whom the assays failed, resulting in a final sample size of 43 African American and 46 Caucasian men. The six CpG sites demonstrated moderate correlations with one another in tumor tissue (Spearman rho: 0.30-0.60, p-value